|
US3120564A
(en)
|
1960-01-13 |
1964-02-04 |
American Cyanamid Co |
Alkenoylamino benzophenones
|
|
US3903106A
(en)
|
1974-04-12 |
1975-09-02 |
Lilly Co Eli |
Pyrazole-3-carboxylic acids
|
|
US3895027A
(en)
*
|
1974-04-12 |
1975-07-15 |
Lilly Co Eli |
Process for preparing pyrazole-3-carboxylic acids
|
|
ZA825719B
(en)
|
1981-09-03 |
1983-06-29 |
Recordati Chem Pharm |
Alkanoylanilides
|
|
JPS58179838A
(ja)
|
1982-04-14 |
1983-10-21 |
Konishiroku Photo Ind Co Ltd |
画像形成方法
|
|
US5256791A
(en)
|
1992-03-02 |
1993-10-26 |
Pfizer Inc. |
Preparation of intermediates in the synthesis of quinoline antibiotics
|
|
EP0722441A1
(en)
*
|
1993-10-06 |
1996-07-24 |
E.I. Du Pont De Nemours & Company Incorporated |
Herbicidal heteroaryl substituted anilides
|
|
DE4341403A1
(de)
|
1993-12-04 |
1995-06-08 |
Basf Ag |
N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
|
|
US5475116A
(en)
|
1994-04-29 |
1995-12-12 |
Pfizer Inc. |
Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
|
|
JPH0912547A
(ja)
|
1995-06-23 |
1997-01-14 |
Chisso Corp |
ニューキノロン系化合物中間体の製造方法
|
|
WO1997030030A1
(en)
|
1996-02-13 |
1997-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Indole derivatives
|
|
JPH1072434A
(ja)
*
|
1996-04-08 |
1998-03-17 |
Nissan Chem Ind Ltd |
２，４−置換アニリン誘導体
|
|
US5968929A
(en)
|
1996-10-30 |
1999-10-19 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
|
US6184380B1
(en)
|
1999-01-25 |
2001-02-06 |
Pfizer Inc. |
Process for preparing naphthyridones and intermediates
|
|
US7019142B2
(en)
|
1998-01-16 |
2006-03-28 |
Pfizer Inc. |
Process for preparing naphthyridones and intermediates
|
|
US6590118B1
(en)
|
1999-09-29 |
2003-07-08 |
Novo Nordisk A/S |
Aromatic compounds
|
|
HUP0301391A3
(en)
|
2000-02-11 |
2010-03-29 |
Vertex Pharma |
Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
|
|
DE60119047D1
(de)
|
2000-08-31 |
2006-06-01 |
Pfizer |
Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer
|
|
EE200300189A
(et)
|
2000-10-19 |
2003-10-15 |
Pfizer Products Inc. |
Sillatud piperasiinderivaadid
|
|
EP1491541B1
(en)
|
2001-03-30 |
2007-01-24 |
Pfizer Products Inc. |
Pyridazinone aldose reductase inhibitors
|
|
CN100506817C
(zh)
*
|
2001-08-15 |
2009-07-01 |
纳幕尔杜邦公司 |
用于防治无脊椎害虫的邻-杂环取代的芳基酰胺类化合物
|
|
US20040034019A1
(en)
|
2002-08-08 |
2004-02-19 |
Ronald Tomlinson |
Piperazine and piperidine derivatives
|
|
US20040082641A1
(en)
|
2002-10-28 |
2004-04-29 |
Rytved Klaus Asger |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
|
EP1558245A2
(en)
|
2002-10-28 |
2005-08-03 |
Novo Nordisk A/S |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
|
ATE400553T1
(de)
|
2002-12-10 |
2008-07-15 |
Ranbaxy Lab Ltd |
3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
|
|
EP1590345A1
(en)
|
2002-12-23 |
2005-11-02 |
Ranbaxy Laboratories, Ltd. |
Xanthine derivatives as muscarinic receptor antagonists
|
|
DE60225195T2
(de)
|
2002-12-23 |
2009-02-26 |
Ranbaxy Laboratories, Ltd. |
Flavaxat-derivate als muscarin-rezeptor antagonisten
|
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
RS20060190A
(sr)
|
2003-10-14 |
2008-08-07 |
Pfizer Products Inc., |
Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
|
|
EP1717225A4
(en)
|
2004-02-18 |
2009-10-21 |
Kyorin Seiyaku Kk |
BICYCLIC AMID DERIVATIVES
|
|
MX2007000015A
(es)
|
2004-06-22 |
2007-03-07 |
Schering Corp |
Ligandos de receptor de canabinoide.
|
|
DE102004039280A1
(de)
|
2004-08-13 |
2006-02-23 |
Merck Patent Gmbh |
1,5-Diphenyl-pyrazole
|
|
MX2007002136A
(es)
|
2004-09-01 |
2007-04-02 |
Pfizer Prod Inc |
Antagonistas amino azabiciclicos del receptor 3 de la histamina.
|
|
US20100016400A1
(en)
|
2004-11-19 |
2010-01-21 |
Naresh Kumar |
Azabicyclic muscarinic receptor antagonists
|
|
CN1944398A
(zh)
|
2005-01-11 |
2007-04-11 |
中国医学科学院药物研究所 |
新的苯甲酰胺类化合物及其制法和药物用途
|
|
GEP20105053B
(en)
|
2005-04-08 |
2010-07-26 |
Pfizer Prod Inc |
Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
|
|
US20090124600A1
(en)
|
2005-04-19 |
2009-05-14 |
Layton Mark E |
N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
|
|
MX2007014180A
(es)
|
2005-05-10 |
2008-01-14 |
Vertex Pharma |
Derivados biciclicos como moduladores de canales de iones.
|
|
GB0510204D0
(en)
|
2005-05-19 |
2005-06-22 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
|
WO2007029086A2
(en)
|
2005-09-05 |
2007-03-15 |
Ranbaxy Laboratories Limited |
Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
|
|
AU2006305619A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
|
WO2008010061A2
(en)
|
2006-07-17 |
2008-01-24 |
Glenmark Pharmaceuticals S.A. |
3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
|
|
GB2454615A
(en)
|
2006-07-21 |
2009-05-13 |
Lupin Ltd |
Antidiabetic azabicyclo (3.1.0) hexan compounds
|
|
PE20080948A1
(es)
|
2006-07-25 |
2008-09-10 |
Irm Llc |
Derivados de imidazol como moduladores de la senda de hedgehog
|
|
EP2059505A2
(en)
|
2006-09-04 |
2009-05-20 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
CA2672373C
(en)
|
2006-12-19 |
2011-08-30 |
Pfizer Products Inc. |
Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
|
|
EP2132196A1
(en)
|
2007-02-26 |
2009-12-16 |
Pfizer Products Inc. |
Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
|
|
WO2008117229A1
(en)
|
2007-03-23 |
2008-10-02 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
AR069126A1
(es)
|
2007-10-31 |
2009-12-30 |
Janssen Pharmaceutica Nv |
Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
|
|
WO2009090548A2
(en)
|
2008-01-17 |
2009-07-23 |
Glenmark Pharmaceuticals, S.A. |
3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
|
|
WO2009152027A1
(en)
|
2008-06-12 |
2009-12-17 |
Merck & Co., Inc. |
5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
|
|
PT2358697E
(pt)
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
|
MA33260B1
(fr)
|
2009-04-08 |
2012-05-02 |
Actelion Pharmaceuticals Ltd |
6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
|
|
US9149465B2
(en)
|
2009-05-18 |
2015-10-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
|
AR076687A1
(es)
|
2009-05-18 |
2011-06-29 |
Infinity Pharmaceuticals Inc |
Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
|
|
CN103140134B
(zh)
|
2010-07-23 |
2015-07-29 |
默沙东公司 |
新吡咯烷衍生的β3肾上腺素能受体激动剂
|
|
US20170119786A1
(en)
|
2011-03-08 |
2017-05-04 |
3-V Biosciences, Inc. |
Heterocyclic modulators of lipid synthesis
|
|
US8772277B2
(en)
|
2011-08-04 |
2014-07-08 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
WO2013039802A1
(en)
|
2011-09-16 |
2013-03-21 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
PT2758394E
(pt)
|
2011-09-19 |
2015-04-22 |
Suven Life Sciences Ltd |
Compostos heteroarilo como ligandos de recetores 5-ht4
|
|
WO2013118138A1
(en)
|
2011-12-13 |
2013-08-15 |
Laboratories Ltd Mylan |
Novel process for the preparation of renin inhibitors
|
|
TWI566701B
(zh)
|
2012-02-01 |
2017-01-21 |
日本農藥股份有限公司 |
芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法
|
|
EP2925322B1
(en)
|
2012-11-29 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
WO2014164543A1
(en)
|
2013-03-13 |
2014-10-09 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
AU2014229283B2
(en)
|
2013-03-14 |
2016-07-28 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
KR101556318B1
(ko)
|
2013-05-15 |
2015-10-01 |
한국과학기술연구원 |
칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
|
|
WO2014199164A1
(en)
|
2013-06-12 |
2014-12-18 |
Ampla Pharmaceuticals, Inc. |
Diaryl substituted heteroaromatic compounds
|
|
HUE049253T2
(hu)
|
2014-09-19 |
2020-09-28 |
Lilly Co Eli |
A tranziens receptor potenciál A1 ion csatorna gátlása
|
|
CN104370899A
(zh)
|
2014-10-23 |
2015-02-25 |
南京工业大学 |
一种含1,2,4-噁二唑结构的甲酰苯胺类化合物及其制备方法与应用
|
|
CN106432255A
(zh)
|
2015-08-11 |
2017-02-22 |
扎夫根公司 |
烟曲霉素醇螺环化合物和制备和使用其的方法
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
WO2017053706A1
(en)
|
2015-09-23 |
2017-03-30 |
The General Hospital Corporation |
Tead transcription factor autopalmitoylation inhibitors
|
|
WO2017058716A1
(en)
|
2015-09-28 |
2017-04-06 |
Vivace Therapeutics, Inc. |
Tricyclic compounds
|
|
EP3156404A1
(en)
|
2015-10-15 |
2017-04-19 |
Inventiva |
New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
|
|
WO2017096045A1
(en)
|
2015-12-02 |
2017-06-08 |
Kyras Therapeutics, Inc. |
Multivalent ras binding compounds
|
|
SG11201805286RA
(en)
|
2015-12-24 |
2018-07-30 |
Kyowa Hakko Kirin Co Ltd |
α,β-UNSATURATED AMIDE COMPOUND
|
|
SI3397631T1
(sl)
|
2015-12-29 |
2022-01-31 |
Pfizer Inc. |
Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
|
|
WO2017207430A1
(en)
|
2016-05-31 |
2017-12-07 |
Chiesi Farmaceutici S.P.A. |
Imidazolone compounds as human neutrophil elastase inhibitors
|
|
CA3026149A1
(en)
|
2016-06-02 |
2017-12-07 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
|
JP6721723B2
(ja)
|
2016-06-27 |
2020-07-15 |
モグ リサーチ センター リミテッドＭｏｇｈｕ Ｒｅｓｅａｒｃｈ Ｃｅｎｔｅｒ Ｌｔｄ． |
イソキサゾリン環を含むピリジン系化合物及び除草剤としての該用途
|
|
US10793504B2
(en)
|
2016-08-23 |
2020-10-06 |
Recurium Ip Holdings, Llc |
Methods for cross coupling
|
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
EP3548476A4
(en)
|
2016-12-02 |
2020-05-20 |
Quentis Therapeutics, Inc. |
SMALL MOLECULAR IRE1 INHIBITORS
|
|
CA3047002A1
(en)
|
2017-01-17 |
2018-07-26 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
EP3606921B1
(en)
|
2017-04-06 |
2022-06-01 |
Inventiva |
New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma.
|
|
WO2018204532A1
(en)
|
2017-05-03 |
2018-11-08 |
Vivace Therapeutics, Inc. |
Non-fused tricyclic compounds
|
|
WO2018208987A2
(en)
|
2017-05-10 |
2018-11-15 |
Forge Therapeutics, Inc. |
Antibacterial compounds
|
|
US11447471B2
(en)
|
2017-06-23 |
2022-09-20 |
Kyowa Kirin Co., Ltd. |
α,β-unsaturated amide compound
|
|
US11192865B2
(en)
*
|
2017-08-21 |
2021-12-07 |
Vivace Therapeutics, Inc. |
Benzosulfonyl compounds
|
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
|
US10287222B1
(en)
|
2017-10-20 |
2019-05-14 |
Uop Llc |
Process and apparatus for desorbent recovery
|
|
JP7264906B2
(ja)
|
2017-11-01 |
2023-04-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
|
|
PE20201170A1
(es)
|
2017-11-01 |
2020-10-28 |
Bristol Myers Squibb Co |
Compuestos biciclicos en puente como moduladores del receptor farnesoide x
|
|
US11524943B1
(en)
|
2017-12-06 |
2022-12-13 |
Vivace Therapeutics, Inc. |
Benzocarbonyl compounds
|
|
IL276411B2
(en)
|
2018-02-02 |
2024-04-01 |
Univ Vanderbilt |
M4 muscarinic acetylcholine receptor antagonists
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
WO2019204505A2
(en)
|
2018-04-18 |
2019-10-24 |
Theras, Inc. |
K-ras modulators with a vinyl sulfonamide moiety
|
|
EP3802543A1
(en)
|
2018-05-31 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Therapeutic compounds
|
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
WO2020073031A1
(en)
|
2018-10-05 |
2020-04-09 |
New York University |
Fused bicyclic heterocycles as thereapeutic agents
|
|
EP3866798A4
(en)
|
2018-10-15 |
2022-07-13 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
|
|
MX2021004191A
(es)
|
2018-10-15 |
2021-05-27 |
Nurix Therapeutics Inc |
Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
|
|
US20210403415A1
(en)
|
2018-10-26 |
2021-12-30 |
The Trustees Of Indiana University |
Compounds and methods to attenuate tumor progression and metastasis
|
|
TWI835945B
(zh)
|
2018-12-14 |
2024-03-21 |
南韓商柳韓洋行股份有限公司 |
3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
KR102866499B1
(ko)
|
2019-03-15 |
2025-10-02 |
더 제너럴 하스피탈 코포레이션 |
Tead 전사인자의 신규한 소분자 저해제
|
|
EP3947368B1
(en)
|
2019-04-04 |
2025-09-03 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
|
|
WO2020219650A1
(en)
|
2019-04-23 |
2020-10-29 |
Dana-Farber Cancer Institute, Inc. |
Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
|
|
UA130430C2
(uk)
|
2019-05-31 |
2026-02-18 |
Янссен Фармацевтика Нв |
НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
|
|
CA3139018A1
(en)
|
2019-05-31 |
2020-12-03 |
Chiesi Farmaceutici S.P.A. |
Amino quinazoline derivatives as p2x3 inhibitors
|
|
CA3141826A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3142351A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
DK4299135T3
(da)
|
2019-06-18 |
2025-09-08 |
Pfizer |
Benzisoxazol-sulfonamid-derivater
|
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
|
BR112022010924A2
(pt)
|
2019-12-06 |
2022-09-06 |
Vertex Pharma |
Tetra-hidrofuranos substituídos como moduladores de canais de sódio
|
|
CA3162348A1
(en)
|
2019-12-24 |
2021-07-01 |
Nathanael S. Gray |
Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
|
|
CN115210227A
(zh)
|
2020-03-04 |
2022-10-18 |
基因泰克公司 |
作为tead抑制剂的异双功能分子
|
|
CA3180846A1
(en)
|
2020-06-03 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
CA3205726A1
(en)
|
2021-01-25 |
2022-07-28 |
Alfredo C. Castro |
Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
|
|
WO2023060227A1
(en)
|
2021-10-07 |
2023-04-13 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|